ArticleBMC microbiology2026
Detection of carbapenem resistance and its attributable genes in Acinetobacter baumannii isolated from cardiac patients at a referral cardiac hospital of Kathmandu.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Characterization ofAntibiotics (Basel, Switzerland) · 2026Article
- High burden of blaBMC microbiology · 2026Article
- blaOXA-23/blaNDM co-carriage among clinical Acinetobacter baumannii isolates from southern Vietnam and its association with multiclass antimicrobial resistance.Le infezioni in medicina · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcinetobacter baumannii has emerged as a major nosocomial pathogen due to its remarkable ability to develop resistance to multiple antibiotics including carbapenems. The objective of this study was to assess the carbapenem resistance and detect carbapenem-resistant genes in clinical isolates of A. baumannii.
methodsA cross-sectional study was conducted in Shahid Gangalal National Heart Centre, Kathmandu during February to September 2024. A total of 42 A. baumannii were isolated from different clinical specimens and identified. Antibiotic susceptibility test was performed by Kirby-Bauer disc diffusion method and carbapenemase production was assessed using modified carbapenem inactivation method and EDTA-carbapenem inactivation method. Carbapenem-resistant genes were detected through polymerase chain reaction. Among 1607 samples tested, 349 were culture positive for bacteria.
resultsThe prevalence of A. baumannii was 12% (42/349). Among the 42 A. baumannii isolates, 88.1% were resistant to carbapenems. Metallo-β-lactamase production was observed in 35.7% and multidrug resistance in 83.3% isolates. Resistance rates were highest against cefotaxime, cefepime and carbapenems. The blaOXA-23 gene was detected in 69.1% of the isolates, blaNDM-1 in 66.7%, and blaVIM in 14.3%, but none of the isolates harbored the blaIMP. Co-occurrence of blaOXA-23 and blaNDM-1 genes was detected in 20 (47.6%) isolates, blaOXA-23, blaNDM-1 and blaVIM in 4 (9.5%) isolates, and blaNDM-1 and blaVIM in 1 (2.4%) isolate.
conclusionThis study showed a high burden of carbapenems resistant and multi-drug resistant A. baumannii, likely contributed by the co-occurrence of carbapenem resistant genes. These findings provide valuable insights for clinical management and infection control of A. baumannii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.